Malaria

• 1. Introduction

  ›

  Malaria has placed the greatest selective pressure on the human genome in recent history. It has reshaped our blood, our chromosomes, and the very shape of our red cells. In 2024, an estimated 282 million people fell ill with it across 80 endemic countries, and 610,000 died. Children under five made up 75% of the deaths in Africa that year. The disease arrives by the bite of a female Anopheles mosquito, a single insect carrying single-celled parasites of the genus Plasmodium. Yet for thousands of years no one knew the cause. The Romans named it after bad air rising from their swamps. So how did a parasite small enough to hide inside one blood cell come to alter empires, drug cabinets, and our own DNA? How does it slip past the immune system again and again? And why, after two global campaigns to wipe it out, does it still circle the equator?

• 2. The Parasite's Two Worlds

  ›

  Within five to twenty-five days of entering the body, a single infected liver cell can harbor up to 40,000 parasites. This is where malaria begins its silent work. When a mosquito bites, it injects a mobile form called sporozoites into the bloodstream. These travel to the liver and invade its cells, growing and dividing without causing a single symptom.

  Merozoites are the smaller form released when those liver cells break down, spilling into the blood. There they invade red blood cells, and inside each one a parasite replicates over 24 to 72 hours to form 16 to 32 new merozoites. The red cell bursts, the new merozoites pour out, and the cycle repeats, amplifying the parasite count with every round. Symptoms only appear once there are more than around 100,000 parasites in each milliliter of blood.

  Gametocytes are the parasite's sexual stage, and only a small portion of parasites become them. These develop in the bone marrow for eleven days, then return to the blood to wait. When another mosquito bites, it swallows them, and inside the insect they reproduce sexually and form new sporozoites that travel to its salivary glands. Two species, P. vivax and P. ovale, leave behind a dormant form in the liver called a hypnozoite, which can wake weeks or months later and cause the disease to relapse.

• 3. A Master Of Disguise

  ›

  Roughly 10% of the Plasmodium genome is devoted to avoiding or subverting the immune system. That figure hints at how much of this parasite's existence is spent hiding. In the liver, specialised macrophages called Kupffer cells are meant to destroy foreign material, but sporozoites attack and neutralise them, passing through the dying cells to reach the liver tissue beneath.

  Merosomes are the parasite's escape vehicle from the liver. The infected cell releases merozoites in these batches, cloaked in a piece of the host cell's own membrane, letting them sneak past the remaining Kupffer cells. Free in the bloodstream, the merozoites face white blood cells that hunt their surface markers. The parasite answers with antigenic polymorphism, expressing a different surface variant at each stage, a moving target the adaptive immune system cannot catch.

  Rosettes are clumps where an infected red cell at the centre is shielded by uninfected cells bound around it. P. falciparum makes adhesive proteins that appear as knobs on infected cells, and these knobs let the cells either form rosettes or stick to the walls of blood vessels in the brain, lungs, and placenta. By sequestering in tissue, the cells dodge the spleen, but they also choke the function of the very organs they hide in.

• 4. When Vital Organs Fail

  ›

  Cerebral malaria can kill within forty-eight hours of the first symptoms. It is a form of severe malaria where infected red cells block capillaries in the brain, triggering an immune reaction that damages the blood-brain barrier. Sufferers grow confused, then seize, then fall into coma, and survivors may carry long-term neurological damage. Almost all severe malaria is caused by P. falciparum, the species responsible for the vast majority of deaths.

  Acute respiratory distress syndrome strikes in up to 25% of cases, when damage to the capillary lining injures the air sacs of the lungs. Victims gasp for breath, and their lips turn a bluish cyanosis. Once symptoms begin, this complication kills around 40% of adults. Severe anaemia, driven by the destruction of red cells and the bone marrow's reduced output, is a major cause of death in children under five.

  Blackwater fever takes its name from the urine it discolours, when haemoglobin from ruptured red cells leaks out, often just before the kidneys fail. In pregnancy the danger doubles back on two lives at once. Parasites accumulate in the placenta, contributing to low birth weight, preterm labor, miscarriage, and stillbirth. Pregnant women are three times more likely to develop severe malaria, because pregnancy itself modifies the immune response.

• 5. Written Into Our Blood

  ›

  Sickle cell trait is one of evolution's bargains struck against malaria. The trait changes the haemoglobin molecule so that, under low oxygen or dehydration, the molecules stick together and distort the red cell into a curved sickle shape. Early in an infection, the parasite can make infected cells sickle, and those cells are then cleared from circulation sooner, breaking the parasite's cycle.

  Homozygous individuals, carrying two copies of the abnormal beta allele, develop sickle-cell anaemia and a shorter life. Heterozygous individuals, with one abnormal allele and one normal one, gain resistance to malaria without the severe anaemia. In malaria-prone regions the trait survives precisely because the protected heterozygous form outweighs the cost of the homozygous one.

  Thalassaemia traits, glucose-6-phosphate dehydrogenase deficiency, and the absence of Duffy antigens on red blood cells also lend partial protection. These genetic factors are the fingerprints of a parasite that has shaped human inheritance. The pressure came chiefly from P. falciparum, and its toll explains why the human body itself became a battleground.

• 6. Finding The Hidden Enemy

  ›

  Charles Louis Alphonse Laveran, a French army doctor at the military hospital of Constantine in Algeria, first saw the parasites inside infected red cells in 1880. It was the first time a protist was identified as a cause of disease, and it won him the 1907 Nobel Prize for Physiology or Medicine. The cause had a face at last.

  Sir Ronald Ross visited Sir Patrick Manson at his house on Queen Anne Street in London in April 1894, beginning four years of research. Working at the Presidency General Hospital in Calcutta, Ross proved the parasite's full life cycle in mosquitoes in 1897, isolating malaria parasites from the salivary glands of mosquitoes that had fed on infected birds. He received the 1902 Nobel Prize in Medicine. In 1898 Giovanni Battista Grassi and Giuseppe Bastianelli, with Amico Bignami, showed the transmission in humans and presented it to the Accademia dei Lincei.

  Giemsa-stained blood under a light microscope remains the gold standard for diagnosis today. Microscopists read a thick film to scan many cells quickly and a thin film to identify the species, detecting parasites down to about 100 per microliter. Rapid diagnostic tests detect parasite proteins from a fingerstick sample, though the common HRP2 test can linger up to five weeks after treatment. In April 2026, the World Health Organization prequalified three rapid tests targeting the protein pf-LDH to catch P. falciparum strains with pfhrp2 deletions that evade older tests.

• 7. Bark, Wormwood, And Resistance

  ›

  The bark of the cinchona tree, growing on the slopes of the Andes mainly in Peru, gave the world its first effective treatment. Indigenous peoples of Peru made a tincture of it to control fever, and the Jesuits brought the remedy to Europe around 1640. By 1677 it appeared in the London Pharmacopoeia. In 1820 the French chemists Pierre Joseph Pelletier and Joseph Bienaimé Caventou extracted and named its active ingredient, quinine, which reigned as the main treatment until the 1920s.

  Artemisia annua had been used by Chinese herbalists for 2,000 years before it transformed modern treatment. In 1596 Li Shizhen recommended a tea made from qinghao for malaria in his Compendium of Materia Medica. In the 1970s the Chinese scientist Tu Youyou and colleagues discovered artemisinins from the plant, drawing on a fourth-century text written in 340 by Ge Hong. Tu received the 2015 Nobel Prize in Physiology or Medicine.

  Chloroquine replaced quinine in the 1940s, and P. falciparum began resisting it in the 1950s. Resistance to proguanil came even faster, the drug introduced in 1948 and resistance noted the next year, in 1949. Partial resistance to artemisinin emerged in Southeast Asia in 2001 and has since reached parts of Africa. To stay ahead, guidelines since 2001 generally require two drugs in combination, one of them an artemisinin derivative, with the most common first-line treatment for uncomplicated P. falciparum being artemether-lumefantrine taken orally over three days.

• 8. Nets, Vaccines, And A Stalled Campaign

  ›

  Almost 2.5 billion insecticide-treated nets have been distributed worldwide since 2004, with 2.2 billion of them, or 87 per cent, going to sub-Saharan Africa. A 2025 Malaria Atlas Project analysis estimated that malaria interventions in Africa prevented 1.57 billion cases from 2000 to 2024, with nets accounting for 72% of cases averted. Treated nets are estimated to be twice as effective as untreated ones, offering more than 70% protection compared with no net. Yet by 2023 only 52% of children in sub-Saharan Africa were sleeping under them.

  RTS,S, known as Mosquirix, became the first approved vaccine targeting P. falciparum, completing clinical trials in 2014. Pilot programs began in 2019 in Ghana, Kenya, and Malawi, focused on children under five. By 2023 three million children had received it, and childhood mortality from all causes fell by 13%. The second vaccine, R21/Matrix-M, showed 77% efficacy in early trials and was endorsed by the WHO in 2023.

  The Global Malaria Eradication Program of 1955 to 1969 leaned heavily on DDT and cleared the disease from North America, Europe, and much of the Caribbean before it faltered. Failure to sustain it, rising DDT tolerance, and chloroquine resistance brought a resurgence, and the WHO suspended the effort in 1969. Today mosquitoes are adapting again, biting earlier in the evening and resting outdoors to dodge sprayed walls, a behavioural shift that sustains residual transmission. In Pakistan the 2022 floods produced an eightfold rise in malaria cases within two years, a sign of how climate, conflict, and resistance now press against the goal of a world largely free of malaria by 2050.